Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Equity Income (2018 - 2020)

Arcus Biosciences has reported Equity Income over the past 3 years, most recently at $1.2 million for Q4 2020.

  • Quarterly results put Equity Income at $1.2 million for Q4 2020, changed N/A from a year ago — trailing twelve months through Jun 2021 was $1.2 million (up 226.39% YoY), and the annual figure for FY2020 was $613000.0, up 151.0%.
  • Equity Income for Q4 2020 was $1.2 million at Arcus Biosciences, up from -$131000.0 in the prior quarter.
  • Over the last five years, Equity Income for RCUS hit a ceiling of $1.2 million in Q4 2020 and a floor of -$482000.0 in Q1 2020.
  • Median Equity Income over the past 3 years was -$274500.0 (2018), compared with a mean of -$147300.0.
  • Biggest five-year swings in Equity Income: crashed 172.85% in 2019 and later soared 68.2% in 2020.
  • Arcus Biosciences' Equity Income stood at -$323000.0 in 2018, then decreased by 10.53% to -$357000.0 in 2019, then surged by 443.42% to $1.2 million in 2020.
  • The last three reported values for Equity Income were $1.2 million (Q4 2020), -$131000.0 (Q2 2020), and -$482000.0 (Q1 2020) per Business Quant data.